11 yearsʼ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial - Cameron, D; Piccart-Gebhart, M J; Gelber, R D (Lancet, 2017)